The federal 7-OH situation moved significantly in 2026, and buyers deserve the process explained without either panic or spin. Here is the timeline and what each step actually means.
The timeline so far
- July 29, 2025 — FDA recommendation. The FDA formally recommended that the DEA place 7-hydroxymitragynine in Schedule I of the Controlled Substances Act. A recommendation is a starting gun, not a decision — scheduling is the DEA’s call, made through rulemaking.
- July 1–6, 2026 — DEA notices of intent. The DEA published two notices of intent (Docket DEA-1570). The first targeted 7-OH above a specified concentration threshold for temporary Schedule I placement, stating an order would be published in the Federal Register on or after August 5, 2026. The second targeted three synthetic, 7-OH-related compounds: mitragynine pseudoindoxyl, MGM-15 and MGM-16.
- August 26, 2026 — the synthetic compounds order takes effect. The temporary scheduling order covering the three synthetic compounds was issued and took effect. Products built on those synthetic compounds are now Schedule I controlled substances at the federal level.
- As of this writing — the 7-OH order itself has not taken effect. The August 5 earliest date passed without the concentrated-7-OH order being published; the comment process extended into September. The order can be published on any day and takes effect on publication. This status is tracked on the compliance page, which is the live reference.
What “above a specified threshold” means
The proposed 7-OH order would apply to 7-hydroxymitragynine above a concentration threshold, not to the compound in all forms. In practice, that is aimed at concentrated extract products — exactly the category this store sells — rather than raw botanical material. If the order issues, the manufacture, distribution and possession of above-threshold 7-OH products would carry Schedule I controls and sanctions at the federal level. The Schedule I explainer covers what that classification means in plain terms.
What it means for buyers, practically
- Nothing changes until the order is published. Until that happens, the current state-by-state picture holds, and checkout continues to enforce it. No order placed today is affected by a rule that does not exist yet.
- If the order issues, the effect is immediate and national. There is no state-by-state negotiation layer under federal scheduling — the what-happens post covers the buyer-side scenarios.
- Watch the compliance page, not the rumor cycle. The Federal Register is the source; the compliance page reflects it. Forum predictions about dates are not tracking.
What does not change either way
The product risk profile. Scheduling changes the legal status of a substance; it does not change its pharmacology. The responsible use guide, the no-mixing rule and the emergency resources apply the same day the order publishes as the day before. That is the part of this story that matters most to any individual buyer, and it is the part no regulation can do your decision-making for.